| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9e409cebfb43867b70fa454807b782b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05da5faa1b435dd6db0733c551b22c93 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2013-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecf8352cd4efb66104799e6bc17c13ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6fb36f724d58ad6d723dee477e5a002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5dae274efe3e13cceeabfa3f64ea222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7225f35539d19139d35c69e0b17e157b |
| publicationDate |
2013-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013274315-A1 |
| titleOfInvention |
Pro-angiogenic genes in ovarian tumor endothelial cell isolates |
| abstract |
A gene profiling signature for ovarian tumor endothelial cells is disclosed herein. The gene signature can be used to diagnosis or prognosis an ovarian tumor, identify agents to treat an ovarian tumor, to predict the metastatic potential of an ovarian tumor and to determine the effectiveness of ovarian tumor treatments. Thus, methods are provided for identifying agents that can be used to treat ovarian cancer, for determining the effectiveness of an ovarian tumor treatment, or to diagnose or prognose an ovarian tumor. Methods of treatment are also disclosed which include administering a composition that includes a specific binding agent that specifically binds to one of the disclosed ovarian endothelial cell tumor-associated molecules and inhibits ovarian tumor in the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016210098-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874622-B2 |
| priorityDate |
2007-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |